AI-Driven Early Detection of Skin Cancer
Recruiting · NCT07144306 · Observational (researchers observe without assigning treatment) · Lead sponsor: Nuvana Healthcare LTD
View the official record on ClinicalTrials.gov →Interventions studied
Smartphone-based AI skin lesion analysis (NuvanaDx platform).
What this trial is about
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Who can take part
Age range
18 Months and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults (≥18 years) presenting with skin lesions suspicious for malignancy.
- Ability to provide informed consent.
Exclusion criteria
- Inability to provide informed consent.
- Poor-quality images unsuitable for AI analysis.
Where it is running
1 location listed.
- Nuvana Healthcare Ltd - London, United Kingdom